Verdinexor: A Novel Oral Therapy for Canine Lymphoma

Approved for one hour California Statutory CEU

**Click Here to RSVP**

7:00pm President does 5 to 10 min Association & Chapter update
7:15pm Sponsor 10 min presentation opportunity
7:15 – 7:30 Speaker starts and finishes with Q & A (1 HOUR); then
depart.

Objective: This presentation will focus on the novel class of drugs called SINE inhibitors and review SINE mechanism of action. We will also look at where this oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense Verdinexor as well as how to monitor their lymphoma patient on Verdinexor, including how to address any potential adverse events.

Speaker: Julie Kluxdal, DVM

Bio: Dr. Julie Kluxdal is a 1998 graduate of the University of Illinois College of Veterinary Medicine. She spent eight years in clinical practice. Her practice experience includes canine, feline, emergency, exotic pet and wildlife medicine. Her career transitioned to the animal health industry when she accepted a position as a Field Technical Services
Veterinarian in 2006 and most recently joined Dechra Veterinary Products as a Professional Services Veterinarian in November 2019. Outside of work Julie enjoys spending time outdoors with her family hiking and biking at home in California. When they can, they enjoy visiting other parts of the United States and the world. Her family includes her
husband, son, a house full of cats and one snake.

Sponsor: